Gene
IDH1
IDH1 is a gene biomarker in the evidence tier "FDA companion diagnostic". This page lists evidence by type: FDA companion diagnostic assertions (5), Assay-provider ledger (40), Actionable biomarkers (7), and 7 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
2 more sections with rows · 2 sections measured, none recorded
FDA companion diagnostic
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention IDH1. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 4 with a planned future start and 4 with no date at all.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 70 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 43 of 8,738 | 0.49% | not measured | |
| 2025 | 41 of 8,875 | 0.46% | not measured | |
| 2024 | 33 of 8,597 | 0.38% | not measured | |
| 2023 | 24 of 8,275 | 0.29% | 118 of 11,460 | 1.03% |
| 2022 | 19 of 8,285 | 0.23% | 101 of 13,598 | 0.74% |
| 2021 | 32 of 8,692 | 0.37% | 119 of 15,045 | 0.79% |
| 2020 | 28 of 7,640 | 0.37% | 97 of 14,459 | 0.67% |
| 2019 | 30 of 7,300 | 0.41% | 87 of 12,159 | 0.72% |
| 2018 | 21 of 6,927 | 0.30% | 78 of 11,854 | 0.66% |
| 2017 | 19 of 6,558 | 0.29% | 63 of 11,595 | 0.54% |
Showing 10 of 37 years.
FDA companion diagnostic assertions (5)
Shown in this order: most recent decision first.
| Diagnostic | Source biomarker wording | Manufacturer | Indication | Decision date |
|---|---|---|---|---|
| Oncomine Dx Target Test | IDH1 | Life Technologies Corporation | Astrocytoma and Oligodendroglioma | 2024-09-18 |
| Abbott RealTime IDH1 | IDH1 | Abbott Molecular, Inc. | Myelodysplastic Syndromes (MDS) | 2023-10-24 |
| Abbott RealTime IDH1 | IDH1 | Abbott Molecular, Inc. | Acute Myeloid Leukemia | 2022-12-01 |
| Oncomine Dx Target Test | IDH1 | Life Technologies Corporation | Cholangiocarcinoma | 2021-08-25 |
| Abbott RealTime IDH1 | IDH1 | Abbott Molecular, Inc. | Acute Myeloid Leukemia | 2018-07-20 |
Assay-provider ledger (40)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| THERMO FISHER SCIENTIFIC (Click-iT EdU kit, TaqMan Low-Density Array reagents, ExpressionSuite/DataAssist software) | Reagent supplier | Clinical validation | 2 | June 01, 2026 |
| GE HealthCare | Context dependent | Clinical validation | 1 | December 03, 2025 |
| MagMAX Cell-Free Total Nucleic Acid Isolation Kit | Reagent supplier | Clinical validation | 1 | October 01, 2025 |
| Maxwell RSC Nucleic Acid Purification Kit (Promega) | Reagent supplier | Clinical validation | 1 | October 01, 2025 |
| Exosome Diagnostics, a Bio-Techne Brand | Diagnostic provider | Clinical validationAnalytical validation | 1 | August 16, 2024 |
Showing 5 of 40 assay-provider companies.
Actionable biomarkers (7)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| IDH1 oncogenic mutation | Idh1 Inhibitors | response-associated | acute myeloid leukemia | Cancer Genome Interpreter |
| IDH1 oncogenic mutation | Venetoclax | response-associated | acute myeloid leukemia | Cancer Genome Interpreter |
| IDH1 oncogenic mutation | Bcl2 Inhibitors | response-associated | acute myeloid leukemia | Cancer Genome Interpreter |
| IDH1 (R132) | Dasatinib | response-associated | biliary tract neoplasm | Cancer Genome Interpreter |
| IDH1 oncogenic mutation | Dasatinib | response-associated | cholangiocarcinoma | Cancer Genome Interpreter |
Showing 5 of 7 actionable-biomarker assertions.
Trial mentions (336)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT02823210 | Trial biospecimen (AACT) |
| NCT02684838 | Trial biospecimen (AACT) |
| NCT01089244 | Trial biospecimen (AACT) |
| NCT06969352 | Trial eligibility (AACT) |
| NCT06176989 | Trial eligibility (AACT) |
Showing 5 of 336 trial mentions.
Target-disease associations (431)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Abnormal sperm morphology | phenotype | Expression Atlas |
| Alzheimer disease | nervous system disease | Literature (Europe PMC) |
| Anal Melanoma | cancer or benign tumor | Cancer Gene Census |
| Anaplastic (Malignant) Meningioma | cancer or benign tumor | Cancer Gene Census |
| Appendix Adenocarcinoma | cancer or benign tumor | Cancer Gene Census |
Showing 5 of 431 associations.
Vendor sourcing (1,167)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| AbbVie Inc. | Trial sponsor | Mentioned in trial textTrial free-text mention | IDH1 | View trial NCT03069352 |
| Abramson Cancer Center | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Prior histopathologically proven diagnosis of astrocytoma (grade 2-4) or oligodendroglioma (grade 2-3) according to the World Health Organization (WHO)... | View trial NCT05345002 |
| Abramson Cancer Center | Trial collaborator | Mentioned in trial textTrial free-text mention | IDH1 | View trial NCT05345002 |
| Abramson Cancer Center | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the ... | View trial NCT05297903 |
| Abramson Cancer Center | Trial sponsor | Mentioned in trial textTrial free-text mention | IDH1 | View trial NCT05297903 |
Showing 5 of 1,167 sourcing records.
Trial-cited literature (932)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Dual FLT3/PIM inhibitor dapolsertib in acute myeloid leukemia: results from the phase 1/2 DIAMOND-01 trial. | Blood neoplasia | 2026 | 2 |
| Protocol for neuro-oncology anywhere 242: Pilot study evaluating telehealth and in-person assessments in patients with glioma receiving oral chemotherapy. | Contemporary clinical trials communications | 2026 | 0 |
| Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma. | Nature medicine | 2025 | 58 |
| Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer. | Journal of hepatology | 2025 | 40 |
| Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2025 | 27 |
Showing 5 of 932 papers.
Protein variant mentions (29)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A341D | 1 | 2015 | PMID 26572169 |
| p.E1222G | 1 | 2010 | PMID 20068184 |
| p.E1234G | 1 | 2010 | PMID 20068184 |
| p.F28L | 1 | 2015 | PMID 25762141 |
| p.F32V | 1 | 2023 | PMID 37459200 |
Showing 5 of 29 variants.
Literature-extracted relations (395)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| NIVOLUMAB | Chemical | associate |
Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations. | 2025 |
| NIVOLUMAB | Chemical | associate |
Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations. | 2025 |
| AZACITIDINE (VIDAZA) | Chemical | negative_correlate |
Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML. | 2025 |
| AZACITIDINE (VIDAZA) | Chemical | negative_correlate |
Olutasidenib alone or combined with azacitidine in patients with mutant IDH1 myelodysplastic syndrome. | 2025 |
| AZACITIDINE (VIDAZA) | Chemical | negative_correlate |
Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML. | 2025 |
Showing 5 of 395 relation assertions.
Organizations publishing (751)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | Hospital | 74 | 2010 to 2025 |
| The University of Texas System | Academic | 68 | 2013 to 2026 |
| Dana-Farber Cancer Institute | Other | 67 | 2009 to 2025 |
| Harvard Medical School | Academic | 51 | 2012 to 2025 |
| Mayo Clinic | Hospital | 47 | 2013 to 2026 |
Showing 5 of 751 organizations.
Where IDH1 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- measurement
- nervous system disease
- nutritional or metabolic disease
- phenotype
- psychiatric disorder
- urinary system disease
340 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda biomarker qualification projects and human sample screening reference.